Total revenue decreased by 6% to $13.07 million in 2025 from $13.90 million in 2024. A net loss of $908,002 was recorded in 2025, a significant decline from a net income of $8,574 in 2024. Operating loss for 2025 was $956,187, compared to an operating profit of $6,901 in 2024. Theranostics Products revenue decreased by 15% to $6.84 million, partly due to an estimated $500,000 in lost sales from raw material supplier outages. Cobalt Products revenue decreased by 26% to $1.75 million, with a Q4 2025 shutdown for hot cell refurbishment delaying approximately $350,000 in revenues to 2026. Calibration & Reference Products revenue increased by 21% to $4.25 million, recovering from 2024 supply issues but offset by an ongoing global outage of Gadolinium-153, which resulted in $0 sales in 2025 compared to $210,000 in 2024. Medical Devices Products revenue significantly increased to $228,951 in 2025 from $8,657 in 2024, though it remains a small portion of total revenue. The asset purchase agreement to sell the Fluorine Products segment and the Planned Uranium De-Conversion Facility to American Fuel Resources (AFR) was mutually terminated on March 11, 2026, due to AFR's inability to secure funding, with Radnostix retaining $170,000 in non-refundable payments. A voluntary recall of specific lots of Dibasic Sodium Phosphate Capsules (provided with Generic Sodium Iodide I-131 kits) was initiated on February 19, 2026, due to out-of-specification capsule weight, resulting in a $75,000 inventory write-off in Q4 2025 and estimated $50,000 in customer credits and $25,000-$75,000 per week in lost revenue in Q1 2026. Refurbishment of Cobalt-60 Processing Hot Cell windows was completed in Q1 2026, extending their life by 15-20 years and expecting $150,000 in annual radiological waste cost savings. Construction of a dedicated Calibration & Reference Products manufacturing facility was completed in Q4 2025, with an NRC license amendment received on January 16, 2026, for equipment installation.